Merck’s $70B Pipeline Target Highlights Oncology, PCSK9 Focus

At the Morgan Stanley Healthcare Conference on September 14, 2026, Merck (MRK) outlined ambitious pipeline ambitions, targeting over $70 billion in revenue by the mid-2030s through 20 assets, with oncology and PCSK9 inhibitors as central pillars. CEO Rob Davis emphasized the company’s focus on advancing 10 assets expected to generate roughly 70% of total pipeline revenue, with oncology alone projected to contribute more than $25 billion. The company’s last twelve months saw revenue of $66.6 billion and a gross profit margin of 75.9%, underscoring its financial strength as it invests in high-growth areas. Merck has raised dividends for 15 consecutive years, maintaining a current yield of 2.36%.